Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 1/2006

01-01-2006 | Original Paper

Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer

Authors: Levent B. Beder, Mehmet Gunduz, Mamoru Ouchida, Esra Gunduz, Akiko Sakai, Kunihiro Fukushima, Hitoshi Nagatsuka, Sachio Ito, Noriyasu Honjo, Kazunori Nishizaki, Kenji Shimizu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2006

Login to get access

Abstract

Purpose: Aims of the study are to narrow-down the hotspot region on 10q21 defined by previous genome-wide loss of heterozygosity (LOH) analysis in head and neck squamous cell carcinomas (HNSCC) and to define candidate tumor suppressor genes (TSG) concerned with 10q21. Materials and methods: LOH analysis was carried out with ten polymorphic microsatellite markers. Expression analysis was performed by semi-quantitative RT-PCR, and mutation analysis by PCR and direct sequencing. Results: LOH analysis on 10q21 in 52 HNSCC indicated distinctive and frequent allelic loss at D10S589 (42%). Among flanking genes, we found the RHOBTB1 gene as a candidate TSG, since an intragenic marker demonstrated the highest LOH (44%). Expression analysis revealed down-regulation of RHOBTB1 mRNA in 37% of tumors. Interestingly, all the five tumors that showed decreased expression of RHOBTB1 were accompanied with LOH, supporting the haploinsufficiency and class 2 TSG characteristics of RHOBTB1. No pathogenic mutation of RHOBTB1 was found. Furthermore, another gene within the region, EGR2, was also taken under scope. LOH frequencies around the EGR2 gene were relatively low (23 and 33%). Albeit semi-quantitative expression analysis of EGR2 demonstrated downregulation in 45% of tumor samples, no relation was found between the expression levels and LOH status. Conclusion: Frequent allelic loss and decreased expression of RHOBTB1 suggested that this gene has a role in tumorigenesis of a subset of HNSCC.
Literature
go back to reference Aspenstrom P, Fransson A, Saras J (2004) Rho GTPases have diverse effects on the organization of the actin filament system. Biochem J 377:327–337CrossRefPubMed Aspenstrom P, Fransson A, Saras J (2004) Rho GTPases have diverse effects on the organization of the actin filament system. Biochem J 377:327–337CrossRefPubMed
go back to reference Beder LB, Gunduz M, Ouchida M, Fukushima K, Gunduz E, Ito S, Sakai A, Nagai N, Nishizaki K, Shimizu K (2003) Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest 83:99–105PubMed Beder LB, Gunduz M, Ouchida M, Fukushima K, Gunduz E, Ito S, Sakai A, Nagai N, Nishizaki K, Shimizu K (2003) Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest 83:99–105PubMed
go back to reference Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D (1990) Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 12:4766–4770CrossRef Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D (1990) Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 12:4766–4770CrossRef
go back to reference Boettner B, Van Aelst L (2002) The role of Rho GTPases in disease development. Gene 286:55–74CrossRef Boettner B, Van Aelst L (2002) The role of Rho GTPases in disease development. Gene 286:55–74CrossRef
go back to reference Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245CrossRefPubMed Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245CrossRefPubMed
go back to reference Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F (1997) Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 14:3059–3066CrossRefPubMed Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F (1997) Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 14:3059–3066CrossRefPubMed
go back to reference Collins T, Stone JR, Williams AJ (2001) All in the family: the BTB/POZ, KRAB, and SCAN domains. Mol Cell Biol 21:3609–3615CrossRefPubMed Collins T, Stone JR, Williams AJ (2001) All in the family: the BTB/POZ, KRAB, and SCAN domains. Mol Cell Biol 21:3609–3615CrossRefPubMed
go back to reference Cook DL, Gerber AN, Tapscott SJ (1998) Modeling stochastic gene expression: implications for haploinsufficiency. Proc Natl Acad Sci USA 95:15641–15646CrossRefPubMed Cook DL, Gerber AN, Tapscott SJ (1998) Modeling stochastic gene expression: implications for haploinsufficiency. Proc Natl Acad Sci USA 95:15641–15646CrossRefPubMed
go back to reference Gasparotto D, Vukosavljevic T, Piccinin S, Barzan L, Sulfaro S, Armellin M, Boiocchi M, Maestro R (1999) Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. Int J Cancer 84:432–436CrossRefPubMed Gasparotto D, Vukosavljevic T, Piccinin S, Barzan L, Sulfaro S, Armellin M, Boiocchi M, Maestro R (1999) Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis. Int J Cancer 84:432–436CrossRefPubMed
go back to reference Gupta S, Luong MX, Bleuming SA, Miele A, Luong M, Young D, Knudsen ES, Van Wijnen AJ, Stein JL, Stein GS (2003) Tumor suppressor pRB functions as a co-repressor of the CCAAT displacement protein (CDP/cut) to regulate cell cycle controlled histone H4 transcription. J Cell Physiol 196:541–556CrossRefPubMed Gupta S, Luong MX, Bleuming SA, Miele A, Luong M, Young D, Knudsen ES, Van Wijnen AJ, Stein JL, Stein GS (2003) Tumor suppressor pRB functions as a co-repressor of the CCAAT displacement protein (CDP/cut) to regulate cell cycle controlled histone H4 transcription. J Cell Physiol 196:541–556CrossRefPubMed
go back to reference Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, Walsh T, Welcsh P, King MC, Wigler MH (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99:13647–13652CrossRefPubMed Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, Walsh T, Welcsh P, King MC, Wigler MH (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99:13647–13652CrossRefPubMed
go back to reference Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedCrossRef Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedCrossRef
go back to reference Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, Ittmann M (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98:11563–11568CrossRefPubMed Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, Ittmann M (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98:11563–11568CrossRefPubMed
go back to reference Lin BT, Gruenwald S, Morla AO, Lee WH, Wang JY (1991) Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J 10:857–864PubMed Lin BT, Gruenwald S, Morla AO, Lee WH, Wang JY (1991) Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J 10:857–864PubMed
go back to reference Mitra P, Xie RL, Medina R, Hovhannisyan H, Zaidi SK, Wei Y, Harper JW, Stein JL, van Wijnen AJ, Stein GS (2003) Identification of HiNF-P, a key activator of cell cycle-controlled histone H4 genes at the onset of S phase. Mol Cell Biol 23:8110–8123CrossRefPubMed Mitra P, Xie RL, Medina R, Hovhannisyan H, Zaidi SK, Wei Y, Harper JW, Stein JL, van Wijnen AJ, Stein GS (2003) Identification of HiNF-P, a key activator of cell cycle-controlled histone H4 genes at the onset of S phase. Mol Cell Biol 23:8110–8123CrossRefPubMed
go back to reference Petersen S, Rudolf J, Bockmuhl U, Deutschmann N, Dietel M, Petersen I (2000) Analysis of the DMBT1 gene in carcinomas of the respiratory tract. Int J Cancer 88:71–76CrossRefPubMed Petersen S, Rudolf J, Bockmuhl U, Deutschmann N, Dietel M, Petersen I (2000) Analysis of the DMBT1 gene in carcinomas of the respiratory tract. Int J Cancer 88:71–76CrossRefPubMed
go back to reference Pinte S, Stankovic-Valentin N, Deltour S, Rood BR, Guerardel C, Leprince D(2004) The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA-binding and repressive properties. J Biol Chem 279:38313–38324CrossRefPubMed Pinte S, Stankovic-Valentin N, Deltour S, Rood BR, Guerardel C, Leprince D(2004) The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA-binding and repressive properties. J Biol Chem 279:38313–38324CrossRefPubMed
go back to reference Poetsch M, Lorenz G, Kleist B (2002) Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. Cancer Genet Cytogenet 132:20–24CrossRefPubMed Poetsch M, Lorenz G, Kleist B (2002) Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. Cancer Genet Cytogenet 132:20–24CrossRefPubMed
go back to reference Ramos S, Khademi F, Somesh BP, Rivero F (2002) Genomic organization and expression profile of the small GTPases of the RhoBTB family in human and mouse. Gene 298:147–157CrossRefPubMed Ramos S, Khademi F, Somesh BP, Rivero F (2002) Genomic organization and expression profile of the small GTPases of the RhoBTB family in human and mouse. Gene 298:147–157CrossRefPubMed
go back to reference Rao UN, Jones MW, Finkelstein SD (2003) Genotypic analysis of primary and metastatic cutaneous melanoma. Cancer Genet Cytogenet 140:37–44CrossRefPubMed Rao UN, Jones MW, Finkelstein SD (2003) Genotypic analysis of primary and metastatic cutaneous melanoma. Cancer Genet Cytogenet 140:37–44CrossRefPubMed
go back to reference Reuter S, Bartelmann M, Vogt M, Geisen C, Napierski I, Kahn T, Delius H, Lichter P, Weitz S, Korn B, Schwarz E (1998) APM-1, a novel human gene, identified by aberrant co-transcription with papillomavirus oncogenes in a cervical carcinoma cell line, encodes a BTB/POZ-zinc finger protein with growth inhibitory activity. EMBO J 17:215–222CrossRefPubMed Reuter S, Bartelmann M, Vogt M, Geisen C, Napierski I, Kahn T, Delius H, Lichter P, Weitz S, Korn B, Schwarz E (1998) APM-1, a novel human gene, identified by aberrant co-transcription with papillomavirus oncogenes in a cervical carcinoma cell line, encodes a BTB/POZ-zinc finger protein with growth inhibitory activity. EMBO J 17:215–222CrossRefPubMed
go back to reference Santarosa M, Ashworth A (2004) Haploinsufficiency for tumour suppressor genes: when you don’t need to go all the way. Biochim Biophys Acta 1654:105–122PubMed Santarosa M, Ashworth A (2004) Haploinsufficiency for tumour suppressor genes: when you don’t need to go all the way. Biochim Biophys Acta 1654:105–122PubMed
go back to reference Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehrle W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi OP, Srivastava S, Pollard HB (2001) ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci USA 98:4575–4780CrossRefPubMed Srivastava M, Bubendorf L, Srikantan V, Fossom L, Nolan L, Glasman M, Leighton X, Fehrle W, Pittaluga S, Raffeld M, Koivisto P, Willi N, Gasser TC, Kononen J, Sauter G, Kallioniemi OP, Srivastava S, Pollard HB (2001) ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci USA 98:4575–4780CrossRefPubMed
go back to reference Srivastava M, Montagna C, Leighton X, Glasman M, Naga S, Eidelman O, Ried T, Pollard HB (2003) Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse. Proc Natl Acad Sci USA 100:14287–14292CrossRefPubMed Srivastava M, Montagna C, Leighton X, Glasman M, Naga S, Eidelman O, Ried T, Pollard HB (2003) Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse. Proc Natl Acad Sci USA 100:14287–14292CrossRefPubMed
go back to reference Trzepacz C, Lowy AM, Kordich JJ, Groden J (1997) Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34. Biol Chem 272:21681–21684CrossRef Trzepacz C, Lowy AM, Kordich JJ, Groden J (1997) Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34. Biol Chem 272:21681–21684CrossRef
go back to reference Unoki M, Nakamura Y (2001) Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20:4457–4465CrossRefPubMed Unoki M, Nakamura Y (2001) Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20:4457–4465CrossRefPubMed
go back to reference Unoki M, Nakamura Y (2003) EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene 22:2172–2185CrossRefPubMed Unoki M, Nakamura Y (2003) EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene 22:2172–2185CrossRefPubMed
go back to reference Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17:4657–4667CrossRefPubMed Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 17:4657–4667CrossRefPubMed
go back to reference Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, Shin DY (1999) p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 274:29677–29682CrossRefPubMed Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, Shin DY (1999) p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 274:29677–29682CrossRefPubMed
Metadata
Title
Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer
Authors
Levent B. Beder
Mehmet Gunduz
Mamoru Ouchida
Esra Gunduz
Akiko Sakai
Kunihiro Fukushima
Hitoshi Nagatsuka
Sachio Ito
Noriyasu Honjo
Kazunori Nishizaki
Kenji Shimizu
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2006
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-005-0033-0

Other articles of this Issue 1/2006

Journal of Cancer Research and Clinical Oncology 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.